Polaryx Therapeutics opened lower at $1.91, compared with its previous close of $1.95. In the last trading session, the stock traded between $1.85 and $1.95. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Polaryx Therapeutics is now worth
$ 5.36
Resulting in a loss of
$ 94.64 (94.64%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.08 (-3.85%)
Day High
$1.95
Day Low
$1.85
Day Open
$1.91
Prev Close
$1.95
Volume
7,468
1W Return
4.87%
1M Return
-6.58%
3M Return
-15.35%
6M Return
-44.69%
1Y Return
-94.64%
Fundamentals
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
9.39
PEG Ratio
-
ROE
-203.48%
ROCE
-203.48%
EPS (TTM)
-
Investment Returns
1 Week
4.87%
1 Month
-6.58%
3 Months
-15.35%
6 Months
-44.69%
9 Months
-48.20%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
9Nov
Polaryx Therapeutics activates first site for Phase 2 SOTERIA trial
Polaryx Therapeutics activated the first clinical site for its Phase 2 SOTERIA basket trial. The trial evaluates PLX-200 across four rare pediatric lysosomal storage disorders (LSDs). Boys Town National Research Hospital in Nebraska will lead screening of eligible pediatric participants. Isabella Herman, M.D., Ph.D., leads the study at the newly activated site.
3 days ago
1Sep
Polaryx Therapeutics appoints Dr. Will Charlton as chief medical officer
Polaryx Therapeutics appoints Dr. Will Charlton as CMO effective September 1, 2026. Dr. Charlton brings nearly two decades of rare disease and pediatric drug development experience. Appointment supports execution of SOTERIA Phase 2 trial planned for initiation in Q4 2026. SOTERIA trial assesses PLX-200 in four lysosomal storage disorders including CLN2 and CLN3. FDA issued safe to proceed letter for SOTERIA trial in October 2025.
2mo ago
25Aug
Polaryx secures FDA nod, $10M funding for SOTERIA trial start in 2026
Polaryx Therapeutics secured FDA authorization and Fast Track Designation for PLX-200 across four LSD indications. Company completed a $10 million financing to support the initiation of the SOTERIA Phase 2 basket trial. SOTERIA trial is planned to initiate in the fourth quarter of 2026 at sites in the US, Europe, and Asia. The open-label study will evaluate safety and clinical activity in pediatric patients aged two to 15 years. CLN2 and CLN3 cohorts will use natural history data as controls rather than placebo arms.
2mo ago
9Jul
HC Wainwright initiates coverage on Polaryx Therapeutics with Buy rating
HC Wainwright & Co. analyst Raghuram Selvaraju has initiated coverage on Polaryx Therapeutics with a Buy rating and a price target of $7.
